Loading…
Underlying
Underlying Price
$6.01
Type
Put
Strike
5.5
Expiration
Dec 4, 2026
DTE
21d
Moneyness
OTM
Intrinsic
$0.00
IBRX 5.5 Put Across Expirations
| Expiration | DTE | Last | Change | Vol | Open Int |
|---|---|---|---|---|---|
| Nov 13, 2026 | 0d | $0.10 | -33.33% | 2 | 123 |
| Nov 20, 2026 | 7d | $0.15 | +0.00% | 1 | 3 |
| Nov 27, 2026 | 14d | — | — | 0 | 25 |
| Dec 4, 2026 | 21d | $0.23 | +0.00% | 1 | 35 |
| Dec 11, 2026 | 28d | $0.27 | +0.00% | 1 | 2 |
| Dec 24, 2026 | 41d | — | — | 0 | 0 |
| Dec 31, 2026 | 48d | — | — | 0 | 0 |
| Jan 15, 2027 | 63d | $0.35 | -12.50% | 151 | 34,019 |
| Jan 21, 2028 | 434d | $1.18 | -25.32% | 10 | 3,931 |
IBRX Profile
immunitybio is a leading registration-stage immuno-oncology and infectious disease company activating both the innate (natural killer cell and macrophage) and adaptive (t cell) immune system. we are developing molecular and product platforms including n-803, aldoxorubicin, and a second-generation adenovirus vector, which are based upon our three key modalities of activating natural killer ('nk') and t cells, tumoricidal macrophages, and memory t cells.